| Date | Title | Description |
| 30.05.2025 | GlycoEra AG: Pioneering a New Era in Autoimmune Disease Treatment | In the world of biotechnology, innovation is the lifeblood that fuels progress. GlycoEra AG is a shining example of this principle. Recently, the company secured $130 million in funding to advance its groundbreaking therapies for autoimmune... |
| 27.05.2025 | GlycoEra AG raises $130 Million to advance therapies for autoimmune diseases |
GlycoEra’s proprietary platform enables the development of best-in-class degraders that target a broad spectrum of extracellular proteins. GlycoEra’s degraders are bispecific molecules that leverage a naturally occurring process to degrade... |
| 08.05.2025 | HAYA Therapeutics: Pioneering the Future of RNA-Guided Therapies | In the world of biotechnology, innovation is the lifeblood. HAYA Therapeutics has just secured a hefty $65 million in Series A funding, a financial boost that could change the landscape of chronic and age-related disease treatment. This fun... |
| 08.05.2025 | HAYA Therapeutics banks $65 million Series A funding |
HAYA Therapeutics is a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics that reprogram disease-driving cell states for rare, common, chronic and age-related diseases. The core of HAYA’s proprie... |
| 21.03.2025 | The Biotech Boom and the Opioid Reckoning: A Tale of Two Industries | In the heart of Europe, a new wave of biotech innovation is rising. Sofinnova Partners has closed a €165 million fund, the Sofinnova Biovelocita II. This fund is a beacon for startups, illuminating the path for groundbreaking therapies. It’... |
| 19.03.2025 | Sofinnova Partners: €165M Biotech Acceleration Fund Closed | Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London, and Milan, announced the final close of Sofinnova Biovelocita II. This fund has exceeded its target, successfully raising €165 million, with s... |
| 12.03.2025 | Sofinnova Partners: €1.2 Billion Raised For Advancing Next Wave Of Life Sciences Innovation | Sofinnova Partners – a leading European venture capital firm in life sciences based in Paris, London, and Milan – announced it had raised €1.2 billion across its platform of investment strategies over the past year, including over €1 billio... |
| 04.03.2025 | VC firm Sofinnova brings in €1.2B over a year to fund up to 60 life sciences companies | Up to 60 new life sciences companies are set to benefit from 1.2 billion euros ($1.27 billion) that Sofinnova Partners has raked in over the past year, the European venture capital firm has announced.
Sofinnova Partners—not to be confused w... |
| 16.10.2024 | Mark Post-Founded Qorium Unveils 35x35cm Cultivated Leather Sample as “Tangible Proof” of a Promising Future | Qorium, a Dutch biotech startup founded by cultivated meat pioneer Mark Post, has announced a significant milestone in scaling up the production of cultivated leather.
Qorium’s platform combines specifically developed cultured cells with ti... |
| 18.07.2024 | Asceneuron's $100M Series C Funding Boosts Alzheimer's Disease Research | Asceneuron, a Lausanne-based clinical-stage biotech company, has recently announced the successful completion of a $100 million Series C financing round. This significant funding boost, led by Novo Holdings and supported by EQT Life Science... |
| 16.07.2024 | Asceneuron closes $100 million series C financing round |
Asceneuron SA, a Lausanne-based clinical-stage biotech company developing small molecules targeting tau protein aggregation, a root cause of neurodegenerative disease, announces its $100 million oversubscribed Series C financing round. The... |
| 09.07.2024 | Endoron Medical: Endograft Stapling Solutions Company Raises $10 Million In Series A Funding | Endoron Medical, a medtech company specializing in innovative endograft stapling solutions for the endovascular repair of abdominal aortic aneurysms, announced the successful closing of its $10 million Series A funding round. This funding r... |
| 16.05.2024 | PCOS infertility treatment developer May Health raises $25M | The startup May Health has gathered $25 million in funding to help continue clinical studies of its less invasive, outpatient procedure for addressing infertility caused by polycystic ovary syndrome, the endocrine disorder commonly known as... |
| 03.04.2024 | From generative chemistry to computational astrophysics, startups employ new methods to fight cancer | Here are a few startups in the cancer space that made headlines recently
The recent revelation of Princess Kate Middleton’s battle with cancer has sent ripples across the globe, reminding us that this disease knows no boundaries of status o... |
| 15.03.2024 | Meet the founder: Bon Vivant’s Stéphane Mac Millan… ‘In the next 10 years, animal-free dairy proteins will be cheaper [than milk proteins from cows]’ | Once upon a time, dairy proteins were made exclusively by lactating mammals. These days, you can produce them in genetically engineered plants or microbes, or even lactating mammary cells grown in a bioreactor.
But is there a market for ‘an... |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 21.02.2024 | Bioptimus: Pioneering AI in Biology | Bioptimus, a Paris-based biotech startup, has secured a hefty $35 million in seed funding to propel its groundbreaking AI foundational model focused on biology. Led by CEO Jean-Philippe Vert, the company aims to revolutionize scientific res... |
| 20.02.2024 | Bioptimus raises $35 million seed round to develop AI foundational model focused on biology | There’s a new generative AI startup based in Paris. But what makes Bioptimus interesting is that it plans to apply everything we’ve collectively learned about AI models over the past few years with a narrow, exclusive focus on biology.
The ... |
| 11.01.2024 | Dutch-based cell-cultured leather company Qorium raises funds; appoints former Nike exec as new CEO | Read this article in:
Limburg-based Qorium, a cell-cultured leather company, announced that it has raised fresh funding from Brightlands Venture Partners and Sofinnova Partners.
Additionally, Michael Newton, a former senior executive at Nik... |
| 05.01.2024 |
Stanford Biodesign co-founder joins Sofinnova Partners | Dr. Josh Makower [Image from his LinkedIn page]Sofinnova Partners — a prominent life sciences venture capital firm based in Paris, London, and Milan — has added Stanford Biodesign co-founder and director Dr. Joshua Makower as an advisory ve... |
| 22.12.2023 | 2024 forecast: Will generative AI find what it needs to deliver for patients? | Large language programs such as ChatGPT and its followers have hogged the spotlight this year, leaving their audience calling for new debates on their ethics and safety. But as the medtech industry watches from the wings—hearing that artifi... |
| 13.12.2023 | Sofinnova opens biotech creation ‘toolbox’ as part of Europe-wide strategy | Venture capital firm Sofinnova Partners has launched a new investment strategy specifically aimed at setting up and accelerating biotech startups across Europe.
The strategy, dubbed Biovelocita, will involve a newly formed team assembled wi... |
| 05.12.2023 | Sofinnova Partners Unveils Sofinnova.AI: A Cutting-edge Artificial Intelligence Platform Set to Transform Its Life Sciences Investment Practice | Combination of real time scientific databases with proprietary data will enable venture capital firm to enhance deal origination and portfolio growth through data-driven insights and strengthened entrepreneurial partnerships
Sofinnova Partn... |
| 16.11.2023 | 'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair | When it comes to bringing together pharma and financiers, the U.S. leads the way with industrial-scale events like J.P. Morgan in San Francisco and BIO in San Diego. But for the chairman of European life sciences VC firm Sofinnova Partners,... |
| 26.10.2023 | L’école AI Secures 3 Million USD in Seed Funding for “Machine Teaching” from Sofinnova | The company’s technology, which removes the engineering complexity around AI systems for image analysis, will initially assist medical professionals
L’école AI, creator of ÉO, a “machine teaching” technology that removes the engineering com... |
| 26.10.2023 | Sofinnova Partners closes €190M Digital Medicine I fund; backs L’école AI in a €2.8M deal | Read this article in:
Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, announced that it has successfully closed Sofinnova Digital Medicine I Fund at €190M, surpassing its target.
Led by Partners E... |
| 26.10.2023 | Sofinnova Partners Raises $200M Digital Medicine Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London, and Milan, closed its Digital Medicine Fund, at $200M.
Led by Partners Edward Kliphuis, and Simon Turner, the fund targets three main areas: enabling ... |
| 08.09.2023 | France-based Gradient Denervation Technologies bag €14M to develop novel pulmonary hypertension therapy | Read this article in:
France-based medtech startup Gradient Denervation Technologies announced on Thursday that it had raised €14M in a Series A round of funding. Asabys Partners led the financing effort through its newly established fund, ... |
| 07.09.2023 | Gradient Denervation Technologies cierra una serie A de €14m liderada por Sabadell Asabys | 07/09/2023
Nota de prensa
GRADIENT DENERVATION TECHNOLOGIES CIERRA UNA SERIE A DE €14M LIDERADA POR SABADELL ASABYS
Gradient Denervation Technologies (“Gradient”), una empresa de dispositivos médicos que desarrolla una solución innovador... |
| 21.06.2023 | Nuage Therapeutics cierra una ronda Seed de €12M liderada por Sofinnova Partners y Asabys. Participan CDTI y BStartup | 21/06/2023
Nota de prensa
NUAGE THERAPEUTICS CIERRA UNA RONDA SEED DE €12M LIDERADA POR SOFINNOVA PARTNERS Y ASABYS. PARTICIPAN CDTI Y BSTARTUP
Nuage Therapeutics (“Nuage”), compañía biotecnológica que desarrolla un motor de descubrimien... |
| 10.05.2023 | Sustainable performance fibers company Werewool raises $3.7 million led by Material Impact and Sofinnova Partners | Werewool won the prestigious ELLE & Polestar Design Towards Zero Award
Our mission as a company is to make the fashion industry compatible with nature.”
— Chui-Lian Lee, Co-founder and CEOBROOKLYN, NY, USA, May 10, 2023/EINPresswire.com... |
| 04.04.2023 | Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences | With the advent and adoption of digital technologies, lines have long blurred among the world of devices, pharma and purely software-driven products. And now, one European venture capital firm has decided to bet on the future of this conver... |
| 31.03.2023 | BioCorteX raises $5 million to unlock drug-bacteria interactions | London-based bio-tech BioCorteX has raised $5 million in Seed funding. The funds will be used to further develop the company's Carbon Mirror platform which is a computer simulation to understand drug-bacteria interactions which hopes to imp... |
| 07.03.2023 | Noema Pharma raises CHF103 million | |
| 12.01.2023 | French pharma Amolyt nets €130 million series C co-led by Sofinnova Partners | Amolyt Pharma, an Ecully, France-based pharma startup working on rare disease treatments, has closed a €130 million series C round.
Amolyt is targeting rare indications affecting the body's hormone supply from endocrine glands. The series C... |
| 11.11.2022 | Sofinnova Partners Appoints Mats Eklund as Partner and Chief Operating Officer | Sofinnova Partners, a life sciences venture capital firm based in Paris, London, and Milan, appointed Mats Eklund as Partner and Chief Operating Officer, effective immediately.
Mr. Eklund will be taking over the helm of Sofinnova’s corporat... |
| 16.05.2022 | VC firm Sofinnova banks $1B from Apollo to invest in early-stage biotech solutions | Biotechs may be seeing their valuations plummet, but Apollo Global Management still wants in. The asset manager has committed up to 1 billion euros ($1.04 billion) in capital commitments to Sofinnova Partners, one of Europe’s largest early-... |
| 06.05.2022 | With Aduhelm in tatters, the search is on for Michel Vounatsos' replacement at Biogen; David Liu, Roger Perlmutter join insitro's SAB | Michel Vounatsos
→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highl... |
| 21.11.2021 | Sofinnova Partners Raises €150M for Its Third Industrial Biotech Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, raised €150m for its third Industrial Biotech Fund.
Sofinnova Industrial Biotech II, which brought the firm’s total assets under management to €2.5 b... |
| 17.11.2021 | VC firm Sofinnova Partners secures €150M to invest in companies leveraging biotech to develop sustainable solutions | Paris-based Sofinnova Partners, a venture capital firm that invests in the life sciences sector from Seed to later-stage, announced that it has secured €150M for its third industrial biotech fund dedicated to environmental impact. With this... |
| 12.11.2021 | GycoEra seals series A financing round at CHF 45 million | |
| 25.10.2021 | Sofinnova Partners Raises €472M to Form Early-Stage Healthcare VC Fund | Sofinnova Partners, a life sciences venture capital firm based in Paris, London and Milan, closed its latest early-stage healthcare venture capital fund, Sofinnova Capital X, at €472 ($548) million.
Capital X, the 10th iteration of Sofinnov... |
| 19.10.2021 | Instacart’s largest acquisition yet is a $350 million bet on cashierless, in-store shopping | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
One factor that will help keep this current fervid pace of dealmaking, even as lock-down orders f... |
| 20.09.2021 | Рискованные инвестиции: разбираемся, стоит ли игра свеч | Рискованные инвестиции: разбираемся, стоит ли игра свеч |
| 20.09.2021 | Рискованные инвестиции: разбираемся, стоит ли игра свеч | Рискованные инвестиции: разбираемся, стоит ли игра свеч |
| 20.09.2021 | Risky investments: is the game worth the candle? | Risky investments: is the game worth the candle? |
| 31.08.2021 | Here’s how French medtech Tissium uses biopolymers for tissue reconstruction; raises €50M | Paris-based Tissium, a privately-owned medtech company that develops biomorphic programmable polymers for tissue reconstruction, announced that it has raised €50M in its Series C round of funding.Investors in this round
The round was led by... |
| 02.08.2021 | Protera Raises $10M to Scale Up Its AI-Driven Next-Generation Proteins | Bioscience startup Protera has raised $10 million in its Series A funding round. The round was led by Sofinnova Partners, with participation from Bimbo Group and ICL Planet.
Protera uses a proprietary AI algorithm called madi™ to rapidly cr... |
| 20.07.2021 | OpenSea raises at a $1.5 billion valuation despite an NFT pullback | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Identity security tools can minimize friction for end users From Ping Identity
Few e... |
| 20.07.2021 | OpenSea raises at a $1.5 billion valuation despite an NFT pullback | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox.
Paid Content Optimizely's CEO on upgrading the marketer experience From Optimizely
Few even in th... |
| 19.07.2021 | Sofinnova Partners Closes €63M Medtech Acceleration Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, closed its medtech acceleration fund, at €63m ($75m USD).
Sofinnova MD Start III enables Sofinnova MD Start’s pioneering team of serial entr... |
| 13.07.2021 | Sofinnova Partners nets $75M for third medtech accelerator fund
Are Real-time Gene Therapy Results Possible? | Shortly after raising an oversubscribed €445 million ($540 million) capital round to support clinical-stage healthcare companies, Sofinnova Partners is back to announce it has gathered €63 million ($75 million) for the final closure of its ... |
| 13.07.2021 | Sofinnova Partners nets $75M for 3rd medtech accelerator fund | Shortly after raising an oversubscribed €445 million ($540 million) capital round to support clinical-stage healthcare companies, Sofinnova Partners is back to announce it has gathered €63 million ($75 million) for the final closure of its ... |
| 08.07.2021 | BREAKING: Micropep’s small peptide ag inputs get $10m from FMC, others | Micropep Technologies, a startup developing peptide-based biological inputs for farms, has raised €8.5 million ($10 million) in Series A funding.
The round was led by Paris-based Supernova Invest. FMC Ventures, the corporate VC arm of US ag... |
| 08.07.2021 | Micropep’s small peptide ag inputs get $10m from FMC, others | Micropep Technologies, a startup developing peptide-based biological inputs for farms, has raised €8.5 million ($10 million) in Series A funding.
The round was led by Paris-based Supernova Invest. FMC Ventures, the corporate VC arm of US ag... |
| 04.03.2021 | London VC Sofinnova Partners pulls in £384M funding to help European clinical-stage companies | The life science industry is entering its next S-curve of growth as various companies are working towards innovations and advancements to create a sustainable environment.
Notably, the cash burns in this industry especially for clinical tri... |
| 03.03.2021 | Sofinnova Partners closes crossover fund at €445 Million | Paris, London and Milan-based Sofinnova Partners has recently announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million. This now comprises the largest crossover investor dedicated late-stage biophar... |
| 03.03.2021 | Sofinnova Partners Closes €445M Late-Stage Healthcare Crossover Fund | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, closed Sofinnova Crossover Fund at €445m ($540m USD).
Led by Cédric Moreau, Partner, the Sofinnova Crossover Fund will maintain its focus on... |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | |
| 01.12.2020 | Noema Pharma raises CHF 54 million in Series A financing round | In 2019, Noema Pharma obtained a seed investment from Sofinnova Partners, a leading European life sciences, venture capital firm based in Paris, London and Milan to embark on a new journey to address orphan neurological disorders characteri... |
| 18.11.2020 | Axon refuerza su liderazgo en el sector de Life Sciences con 2 nuevas inversiones: Forbion & Sofinnova Partners | 18/11/2020
Nota de prensa
AXON REFUERZA SU LIDERAZGO EN EL SECTOR DE LIFE SCIENCES CON 2 NUEVAS INVERSIONES: FORBION Y SOFINNOVA PARTNERS.
Aurora, la plataforma de capital riesgo (venture capital( «Fund of Funds» gestionada por Axon, ref... |
| 16.11.2020 | Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer | Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million (AU$8.2 million) in seed fi... |
| 19.10.2020 | Dr. Joe Anderson Joins Sofinnova Partners | Sofinnova Partners, a European life sciences venture capital firm based in Paris, London and Milan, appointed Dr. Joe Anderson as Partner in the Sofinnova Crossover Fund.
Dr. Anderson has over 25 years’ experience in the healthcare and life... |
| 20.04.2020 | Genespire Receives Investment from Sofinnova Partners | Genespire, a Milan, Italy-based gene-therapy company developing therapies for patients affected by genetic diseases, received an investment from Sofinnova Partners.
The amount of the deal was not disclosed.
The company will use the funds to... |
| 17.10.2019 | Sofinnova Partners Closes Early-Stage Healthcare Fund, at €333M | Sofinnova Partners, a Paris, France-based venture capital firm focused on life sciences, closed its latest early-stage healthcare fund, Sofinnova Capital IX, at €333m.
The new fund has commitments from leading institutional investors, predo... |
| 17.10.2019 | Top tech startup news for today, Thursday, October 17, 2019 | Good morning! Below are some of the top tech startup news for today, Thursday, October 17, 2019.
Airbnb’s quarterly loss reportedly doubled in Q1, a bad sign as investors grow wary of money-losers. Unicorn startups are beginning to face th... |
| 17.10.2019 | Sofinnova Partners raises $370.3 million for its early-stage healthcare fund to invest in healthtech and life sciences startups | Investments in healthcare and Life Sciences startups continue to soar. Now, the sector is boosted by today’s announcement from Sofinnova Partners, a leading European venture capital firm based in Paris, London and Milan and specialized in L... |
| 21.05.2019 | Sofinnova Partners Closes Medtech Acceleration Fund, at €48M | Sofinnova Partners, a European venture capital firm specialized in Life Sciences, closed its third medtech acceleration fund, at €48M.
MD Start III, which closed above its original target of €40m, received support from returning investors B... |
| 15.02.2019 | ABIVAX Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Partners at Market Price | Paris, France, 11 July 2019 at 07:30 pm – ABIVAX SA (the “Company” or “ABIVAX”) (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases... |
| 17.02.2016 | Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners | Corvidia Therapeutics, a biotechnology company focused on the development of precision cardiovascular therapies, announced today that it has raised $26 million in a Series A financing, co-led by seed-investor Sofinnova Partners, and Apple T... |
| - | Sofinnova Partners Closes €445M ($540M) Oversubscribed Late-Stage Healthcare Crossover Fund | PARIS--(BUSINESS WIRE)--Mar 3, 2021--
Sofinnova Partners, a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the final close of the Sofinnova Crossover Fund at €445 million ($540 million ... |
| - | Sofinnova brings in €472 million for Capital X, over €1 billion across the entire platform | Sofinnova Partners, a longtime standard in venture capital, has announced the close of its 10th fund, aptly titled Sofinnova Capital X. The oversubscribed round currently stands at €472 million, bringing the total raise across its multi-fun... |
| - | Paris-based devicemaker SafeHeal gets €40 million booster for transforming digestive surgery | French innovator in the field of digestive surgery and developer of the Colovac device, SafeHeal has raised €40 million funding. The round was co-led by European venture capital firm Sofinnova Partners and Singapore-based Genesis MedTech Gr... |
| - | Comet Bio Announces $22 Million Round of Equity Financing | LONDON, ONTARIO, July 13, 2021 – Comet Bio, manufacturer of healthy, sustainable, and award-winning ingredients, announced today the completion of the company's Series C with an initial close of $22M. The round was led by Open Prairie, a mu... |
| - | French biotech Tissium stitches up €50 million | Parisian biotech firm Tissium has closed a Series C funding round valued at €50 million. The company specialises in the development of biodegradable wound closure compounds, an area traditionally sewn up by stitches. The new funding is expe... |
| - | Synthace raises $35 million, helps scientists automate biology experimentation and insight sharing | London’s Synthace has raised $35 million in a Series C funding round. The life sciences company provides an R&D cloud platform that gives scientists around the globe the ability to automate biology experimentation and insight sharing. T... |
| - | Under pressure, biotech and pharma grapple with how to take climate action | As the health impacts of climate change become harder to ignore, biotechnology and pharmaceutical companies are facing increasing pressure from investors, employees, and government regulators to reduce their carbon emissions, and to make en... |
